NMN (nicotinamide mononucleotide) is one of the most requested “healthy ageing” ingredients from brands abroad, largely because it is a precursor to NAD+, a coenzyme that every cell needs and that declines with age. Japan has a mature NMN supply chain and several NMN products already on the domestic market, which is why brands ask for it by name.
This guide is for brand owners planning an NMN product made in Japan. It covers what the human trials actually show, why NMN’s legal status as a US dietary supplement ingredient became contested and how that was resolved, Japan’s own regulatory framing, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning an NMN product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Human trials of oral NMN are still small and short, and they show that NMN raises blood NAD+ levels reliably — but a 2024 meta-analysis found no significant benefit on glucose or lipid markers, and functional outcomes such as physical performance come from single trials that need repeating.
| Study | Design | Reported result |
|---|---|---|
| Systematic review and meta-analysis, Current Diabetes Reports 2024 (PubMed 39531138, PMC11557618) | 8 randomised controlled trials published 2021–2023, 342 middle-aged and older adults (mainly without diabetes), NMN 250–2,000 mg/day for 14 days to 12 weeks | No significant benefit on fasting glucose, fasting insulin, HbA1c, insulin resistance or the lipid profile |
| Randomised, double-blind, placebo-controlled trial, GeroScience 2024 (PMID 38789831) | 60 healthy older adults, 250 mg/day NMN or placebo for 12 weeks | No difference on the primary outcome (a stepping test); at 12 weeks the NMN group had a shorter 4-m walking time, higher blood NAD+ and metabolites, and lower “daytime dysfunction” and global Pittsburgh Sleep Quality Index scores; fully funded by an ingredient manufacturer, and three of the four authors were its employees |
| Single-arm, open-label trial (no placebo group), Endocrine Journal 2024 (PMID 38191197) | 11 healthy middle-aged Japanese men, 250 mg/day NMN for 8 weeks | NAD+ biosynthesis in blood cells increased and the regimen was well tolerated; a modest reduction in post-meal insulin was reported only in a subgroup of 3 participants with elevated insulin at baseline |
| Single-arm pharmacokinetic and safety study, Endocrine Journal 2020 (PMID 31685720) | 10 healthy men, single oral doses of 100, 250 or 500 mg NMN, no placebo group | No significant changes in vital signs or clinical symptoms; some lab values (bilirubin, creatinine, chloride, glucose) shifted within normal ranges; authors concluded oral NMN was safe and metabolised at these single doses |
Four points to keep in view:
- Size and duration. The 2024 meta-analysis covers 342 people across 8 trials of 14 days to 12 weeks. That is a small, short evidence base for an ingredient marketed around ageing, which by definition plays out over years.
- What was actually measured. Blood NAD+ rising is well established. Whether that translates into a measurable functional benefit is not — the meta-analysis found no significant effect on glucose or lipid markers, and the walking-speed and sleep results come from one 60-person trial that has not yet been independently repeated.
- Funding. The largest single-trial result (walking speed, sleep) came from a study fully funded by the ingredient’s manufacturer, with three of its four authors employed there; its primary outcome, a stepping test, showed no difference. That does not make the result wrong, but it is a material fact to disclose alongside the finding.
- US market status. Separately from the science, NMN’s legal status as a dietary supplement ingredient in the United States was disputed for around three years and only settled in late 2025 (see the market-status section below). If you sell or plan to sell in the US, this is a fact your regulatory adviser needs, independent of the trial evidence.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
NMN itself is treated as a food ingredient in Japan, and it has received Foods with Function Claims notifications for specific, narrow functions — not for anti-ageing or longevity.
Japan’s Ministry of Health, Labour and Welfare revised its food-drug classification (食薬区分) on 31 March 2020, adding β-nicotinamide mononucleotide (NMN) to the list of substances not treated as pharmaceuticals, provided no medicinal effect is claimed for it. That classification is what allows NMN to be used in foods in Japan at all.
Under the separate Foods with Function Claims system, the notifying business submits its own evidence to the Consumer Affairs Agency before sale, and is responsible for it. Two notified NMN products illustrate how narrow the accepted wording is:
- A product notified in 2023 states a function for skin moisture and elasticity in people with dry skin, at 125 mg NMN a day.
- A product notified in April 2025 states a function for maintaining the walking ability that normally declines with age in middle-aged and older adults, at 300 mg NMN a day.
Neither notification claims NMN extends lifespan, reverses ageing or prevents any disease. Two lessons for a brand abroad:
- A Japanese notification covers one narrow, worded function at one tested amount. It is not a general licence to make broader anti-ageing or longevity claims for the ingredient.
- A Japanese notification is not a global endorsement. It is a Japanese regulatory mechanism for products sold in Japan. Your label abroad follows your own market’s rules, including the US market-status history below.
💬 Need an evidence summary for your regulatory adviser that separates Japanese notifications, the independent research, and your target market’s current rules? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe NMN by what has been measured in trials — mainly blood NAD+ levels — not by ageing, lifespan or disease outcomes no product-level trial has tested.
| Safer wording | Wording to avoid |
|---|---|
| ”Contains NMN, studied for its effect on blood NAD+ levels" | "Reverses ageing”, “extends lifespan”, “anti-ageing" |
| "NMN amount per serving, with the study it is based on” | Disease names, or “treats” or “prevents” anything |
| ”Early research; larger studies are still needed" | "Clinically proven” without naming the study, its size and its limits |
How NMN is formulated
NMN is dosed in the hundreds of milligrams and is sensitive to moisture and heat, so the specification has to account for stability as much as the dose itself.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule or tablet | Straightforward, familiar format for a 250–300 mg daily dose | Needs a moisture-resistant blister or bottle with desiccant |
| Sublingual tablet or powder | Marketed on faster absorption | Robust human data comparing sublingual to oral capsule absorption in NMN specifically is limited — avoid absolute claims of superiority |
| Powder stick or drink | Flexible dosing, mixes into a beverage routine | Taste, and stability once dissolved |
Decisions that shape the specification:
- Source and purity. NMN for foods is typically produced by enzymatic or fermentation-based synthesis. Ask the supplier for its production method, purity (commonly reported by HPLC) and a certificate of analysis.
- Stability and packaging. NMN degrades with moisture, heat and light. Blister packs, foil sachets or bottles with desiccant, and storage guidance on the label, all affect shelf life.
- Amount per serving. Match the amount to a study you intend to cite — for example 250 mg/day appears in more than one trial above; higher amounts used in some trials are less studied for safety over long periods.
- Your target market’s status for NMN. In the United States, NMN’s status as a lawful dietary supplement ingredient was excluded by the FDA in 2022, then reversed by two FDA letters dated 29 September 2025 confirming NMN is not excluded from the dietary supplement definition, with further letters to specific ingredient suppliers in December 2025. A New Dietary Ingredient notification is still required before US marketing, and at least one industry body has noted the underlying legal framework behind the original exclusion remains unchanged for other ingredients. Confirm current status directly with your regulatory adviser before you commit to a market — this is a live, evolving area.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
NMN itself has been treated as a food ingredient in Japan since March 2020. Companion ingredients in an ageing-focused formula — botanical extracts especially — need their own check, since some botanicals sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and compare with our astaxanthin and collagen peptide guides if you are building a combined healthy-ageing formula.
Before you ask for a quotation
A factory can quote accurately once the source, the amount, the form and the packaging are fixed.
- NMN source, purity and certificate of analysis
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Packaging and stability requirements (moisture, heat, light)
- Countries you will sell in, and NMN’s current status in each, including the US
💬 Ready to design a Japan-made NMN product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does NMN raise NAD+ levels in humans?
Yes. Rising blood NAD+ is the most consistently reported finding, including in the Japanese trials above. Whether that translates into a measurable health benefit is much less settled.
2. Can an NMN product be marketed as anti-ageing or life-extending?
No. No human trial has tested lifespan or ageing itself as an outcome, and Japan’s own Foods with Function Claims notifications for NMN cover narrow, specific functions such as skin moisture or walking ability — not ageing or longevity.
3. Is NMN legal to sell as a dietary supplement in the United States?
As of late 2025, the FDA confirmed in letters dated 29 September 2025 that NMN is not excluded from the dietary supplement definition, reversing a 2022 position, with further confirming letters to ingredient suppliers in December 2025. A New Dietary Ingredient notification is still required, and this area has changed before, so confirm current status with your regulatory adviser before committing to the US market.
4. Is NMN permitted in foods in Japan?
Yes. Japan’s Ministry of Health, Labour and Welfare added NMN to its non-pharmaceutical substance list on 31 March 2020, and NMN products with Foods with Function Claims notifications are already on the Japanese market.
5. What amount of NMN do the human trials use?
Commonly 250 mg/day for 8–12 weeks in the trials with the clearest results; some meta-analysis trials went up to 2,000 mg/day for as little as 14 days. Match your specification to a specific trial rather than the highest dose you find.
Sources: “Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials”, Current Diabetes Reports 2024 (PubMed 39531138, PMC11557618); “Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study”, GeroScience 2024 (PMID 38789831); “Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men”, Endocrine Journal 2024 (PMID 38191197); “Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men” (Irie et al.), Endocrine Journal 2020 (PMID 31685720); Ministry of Health, Labour and Welfare, food-drug classification notification of 31 March 2020 (mhlw.go.jp); Consumer Affairs Agency Foods with Function Claims notifications; FDA letters of 29 September 2025 and December 2025 on NMN’s dietary supplement status. Checked on 25 September 2026.